Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million on October 27, 2022. Under the agreement, 70% of the Equity Transfer Agreement Consideration shall be paid to Mr. Yu Wu and Mr. Li Xianghao within ten (10) working days and the remaining 30% of the Equity Transfer Agreement Consideration shall be paid to Mr. Yu Wu and Mr. Li Xianghao before December 31, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.96 CNY | -1.82% | +1.06% | -31.12% |
30/04 | Pharmaron Beijing's Profit Rises 17% in 2023 | MT |
29/04 | Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.12% | 4.58B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- 300759 Stock
- News Pharmaron Beijing Co., Ltd.
- Pharmaron Beijing Co., Ltd. entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million.